Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-767 · 1 trial · 3 indications
Blood samples for pharmacokinetics of ABT-767 will be collected at designated time points
| Arm | Type | Description |
|---|---|---|
| ABT-767 | EXPERIMENTAL | ABT-767 monotherapy |
| Name | Type | Description |
|---|---|---|
| ABT-767 | DRUG | ABT-767 once or twice daily for a 28 day cycle |
Inclusion Criteria: 1. Subject must be ≥ 18 years of age. 2. Subjects must have histological or cytological confirmation of locally advanced or metastatic solid tumor, and a documented Breast Cancer Gene 1 or 2 mutation, or high grade serous ovarian, fallopian tube, or primary peritoneal cancer. 3....
ABT-767 is an investigational small molecule studied in oncology for high grade serous ovarian, fallopian tube, or primary peritoneal cancer, as well as other solid tumors. It was evaluated in patients with BRCA1 and BRCA2 mutations. It is not an approved therapy and remains in clinical development.
ABT-767 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie sponsored the clinical research program for this small molecule oncology candidate.
ABT-767 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved for any indication.
ABT-767 was studied in a single Phase 1 trial, NCT01339650, titled Study of ABT-767 in Subjects With BRCA 1 and BRCA 2 Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. The trial enrolled 93 patients in the Netherlands and is completed.
The Phase 1 trial of ABT-767, NCT01339650, was an uncontrolled study. It was not randomized and not double blinded. It enrolled 93 patients with BRCA1 or BRCA2 mutations and solid tumors or high grade serous ovarian, fallopian tube, or primary peritoneal cancer.
Yes. The ABT-767 Phase 1 trial NCT01339650 enrolled patients selected for BRCA1 and BRCA2 mutations, alongside solid tumors or high grade serous ovarian, fallopian tube, or primary peritoneal cancer. Biomarker selection was part of the study design.